A rational approach to the management of chronic migraine

Headache

Volumn 53, Issue 1, 2013, Pages 168-176

  Evans, Randolph W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

chronic migraine; medication overuse; prevention; treatment

Indexed keywords

AMITRIPTYLINE; BOTULINUM TOXIN A; BUTALBITAL; CAFFEINE; DIHYDROERGOTAMINE; FLUOXETINE; GABAPENTIN; KETOROLAC; MEMANTINE; METOCLOPRAMIDE; NAPROXEN; ONDANSETRON; PHENOBARBITAL; PREDNISONE; PREGABALIN; PROPRANOLOL; TIZANIDINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL CRAMP; ACUPUNCTURE; ALLODYNIA; BARIATRIC SURGERY; CHEST TIGHTNESS; CHRONIC DAILY HEADACHE; COGNITIVE THERAPY; DEPRESSION; DIARRHEA; DISEASE DURATION; DRUG ABUSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; EXERCISE; FEEDBACK SYSTEM; HEADACHE; HUMAN; LEG CRAMP; MIGRAINE WITHOUT AURA; NAUSEA; NERVE BLOCK; NERVE STIMULATION; PATIENT COMPLIANCE; PHONOPHOBIA; PHOTOPHOBIA; PRIMARY HEADACHE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; REMISSION; REVIEW; RISK FACTOR; TENSION HEADACHE; TORSADE DES POINTES; TRANSFORMED MIGRAINE; TRIGGER POINT; VISUAL ANALOG SCALE; VOMITING; WITHDRAWAL SYNDROME;

ADULT; CHRONIC DISEASE; FEMALE; HUMANS; MIGRAINE DISORDERS;

EID: 84872114189     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12014     Document Type: Review

References (72)

1. Willis T,. De anima brutorum quae hominis vitalis ac sensitive est exercitationes duae. London, 1672. English version. Two discourses concerning the Soul of Brutes, which is that of the vital and Sensitive of Man, in The Remaining Medical Works of that Famous and Renowned Physician Dr. Thomas Willis, London, 1683: 121-122.
2. Pearce JMS,. Historical aspects of migraine. JNNP. 1986; 49: 1097-1103.
3. Zimmer C,. Soul Made Flesh. The Discovery of the Brain-and How It Changed the World. New York: Free Press; 2004.
4. Hutton S,. Anne Conway: A Woman Philosopher. Cambridge: Cambridge; 2009: 119-123.
5. Halker RB, Hastriter EV, Dodick DW,. Chronic daily headache: An evidence-based and systematic approach to a challenging problem. Neurology. 2011; 76 (Suppl. 2): S37-S43.
6. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD,. Chronic migraine-classification, characteristics and treatment. Nat Rev Neurol. 2012; 8: 162-171.
7. Bigal ME, Serrano D, Reed M, Lipton RB,. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71: 559-566.
8. Bigal ME, Lipton RB,. Excessive acute migraine medication use and migraine progression. Neurology. 2008; 71: 1821-1828.
9. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
10. Evans RW, Baskin SM,. Why do migraineurs abuse butalbital-containing combination analgesics? Headache. 2010; 50: 1194-1197.
11. Saper JR, Lake AE 3rd, Bain PA, et al. A practice guide for continuous opioid therapy for refractory daily headache: Patient selection, physician requirements, and treatment monitoring. Headache. 2010; 50: 1175-1193.
12. Zeeberg P, Olesen J, Jensen R,. Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia. 2006; 26: 1192-1198.
13. Garza I, Schwedt TJ,. Medication overuse headache: Treatment and prognosis. In:, Basow DS, ed. UpToDate. Waltham, MA: UpToDate; 2012. Available at www.uptodate.com.
14. Griffiths RR, Evans SM, Heishman SJ, et al. Low-dose caffeine physical dependence in 196 humans. J Pharmacol Exp Ther. 1990; 255: 1123-1132.
15. Diener HC,. How to treat medication-overuse headache: Prednisolone or no prednisolone? Neurology. 2007; 69: 14.
16. Rabe K, Pageler L, Gaul C, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2012;Oct 23. [Epub ahead of print].
17. Ashkenazi A, Blumenfeld A, Napchan U, et al.; Interventional Procedures Special Interest Section of the American. Peripheral nerve blocks and trigger point injections in headache management-A systematic review and suggestions for future research. Headache. 2010; 50: 943-952.
18. Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: Results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain. 2012;Oct 16. [Epub ahead of print].
19. Raskin NH,. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986; 36: 995-997.
20. Nagy AJ, Gandhi S, Bhola R, Goadsby PJ,. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011; 77: 1827-1832.
21. Hafermann MJ, et al. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: A prospective, observational study. Drug Healthc Patient Saf. 2011; 3: 53-58.
22. Schwartz TH, Karpitskiy VV, Sohn RS,. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002; 42: 519-522.
23. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793-803.
24. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804-814.
25. Dodick D, Gawel M, Agosti R, Miller T, Lei X, Turkel C,. OnabotulinumtoxinA for treatment of chronic migraine: Analysis of the 56-week PREEMPT 2 trial. Presented at the 62nd Annual Meeting of the American Academy of Neurology, Toronto, ON, Canada, April 10-17, 2010.
26. Silberstein SD, Blumenfeld AM, Cady RK, et al. Botulinum neurotoxin type A for treatment of chronic migraine: Analysis of the PREEMPT chronic migraine subgroup with baseline acute headache medication overuse. Presented at the 14th Congress of the International Headache Society, Philadelphia, PA, September 10-13, 2009; PO49.
27. Dodick DW, Turkel CC, DeGryse R, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010; 50: 921-936.
28. Silberstein S, Dodick D, DeGryse R, Lipton R, Turkel C,. The percent of chronic migraine patients who responded to onabotulinumtoxin A treatment per treatment cycle in the PREEMPT clinical program. Neurology. 2012; 78 (AAN Meeting Abstracts 1): P03.230.
29. Oterino A, Ramõn C, Pascual J,. Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: Focus on severe attacks. J Headache Pain. 2011; 12: 235-238.
30. Rothrock J, Bloudek L, Houle T, Andress-Rothrock D, Hanlon C, Varon S,. Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine. Neurology. 2012; 78 (AAN Meeting Abstracts 1): P03.233.
31. Mathew NT, Jaffri SF,. A double-blind comparison of onabotulinumtoxina (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: A pilot study. Headache. 2009; 49: 1466-1478.
32. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU,. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011; 51: 21-32.
33. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27: 814-823.
34. Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: A randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009; 49: 1153-1162.
35. Diener HC, Dodick DW, Goadsby PJ, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009; 29: 1021-1027.
36. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F,. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain. 2008; 9: 37-41.
37. Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: A randomized, placebo-controlled study. Neurology. 2003; 61: 1753-1759.
38. Saper JR, Lake AE III, Cantrell DT, Winner PK, White JR,. Chronic daily headache prophylaxis with tizanidine: A doubleblind, placebo-controlled, multicenter outcome study. Headache. 2002; 2: 470-482.
39. Couch JR, Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011; 51: 33-51.
40. Saper JR, Silberstein SD, Lake AE 3rd, Winters ME,. Double-blind trial of fluoxetine: Chronic daily headache and migraine. Headache. 1994; 34: 497-502.
41. Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM,. Pregabalin in the treatment of chronic migraine: An open-label study. Clin Neuropharmacol. 2010; 33: 35-39.
42. Bermejo PE, Dorado R,. Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol. 2009; 32: 103-106.
43. Pascual-Gõmez J, Gracia-Naya M, Leira R, et al. Zonisamide in the preventive treatment of refractory migraine. Rev Neurol. 2010; 50: 129-132.
44. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S,. Memantine in the preventive treatment of refractory migraine. Headache. 2008; 48: 1337-1342.
45. Diener HC,. Detoxification for medication overuse headache is not necessary. Cephalalgia. 2012; 32: 423-427.
46. Olesen J,. Detoxification for medication overuse headache is the primary task. Cephalalgia. 2012; 32: 420-422.
47. Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012; 78: 976-984.
48. Pascual J,. Combination therapy for chronic migraine: Bad news but not the last word. Neurology. 2012; 78: 940-941.
49. Weibelt S, Andress-Rothrock D, King W, Rothrock J,. Suboccipital nerve blocks for suppression of chronic migraine: Safety, efficacy, and predictors of outcome. Headache. 2010; 50: 1041-1044.
50. Kaniecki RG,. Management of chronic migraine with quarterly pericranial nerve blocks: A prospective 12-month trial. Headache. 2012; 52: 908, P85.
51. Plank S, Goodard J,. The effectiveness of acupuncture for chronic daily headache: An outcomes study. Mil Med. 2009; 174: 1276-1281.
52. Coeytaux RR, Kaufman JS, Kaptchuk TJ, et al. A randomized, controlled trial of acupuncture for chronic daily headache. Headache. 2005; 45: 1113-1123.
53. Park JM, Park SU, Jung WS, Moon SK,. Carthami-Semen acupuncture point injection for chronic daily headache: A pilot, randomised, double-blind, controlled trial. Complement Ther Med. 2011; 19 (Suppl. 1): S19-S25.
54. Yang CP, Chang MH, Liu PE, et al. Acupuncture versus topiramate in chronic migraine prophylaxis: A randomized clinical trial. Cephalalgia. 2011; 31: 1510-1521.
55. Calhoun AH, Ford S,. Behavioral sleep modification may revert transformed migraine to episodic migraine. Headache. 2007; 47: 1178-1183.
56. Varkey E, Cider A, Carlsson J, Linde M,. Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls. Cephalalgia. 2011; 31: 1428-1438.
57. Grazzi L, Andrasik F, D'Amico D, et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: Outcome at 3 years. Headache. 2002; 42: 483-490.
58. Sun-Edelstein C, Mauskop A,. Alternative headache treatments: Nutraceuticals, behavioral and physical treatments. Headache. 2011; 51: 469-483.
59. Bigal ME, Liberman JN, Lipton RB,. Obesity and migraine: A population study. Neurology. 2006; 66: 545-550.
60. Bond DS, Vithiananthan S, Nash JM, Thomas JG, Wing RR,. Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology. 2011; 76: 1135-1138.
61. Novack V, Fuchs L, Lantsberg L, et al. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: A case series. Cephalalgia. 2011; 31: 1336-1342.
62. Guyuron B, Kriegler JS, Davis J, Amini SB,. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg. 2011; 127: 603-608.
63. Liu MT, Armijo BS, Guyuron B,. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites. Plast Reconstr Surg. 2012; 129: 413-419.
64. American Headache Society. American Headache Society urges caution in using any surgical intervention in migraine treatment. 4/16/12. 2012. Available at http://library.constantcontact.com/download/get/file/1101808609332-93/ ahs+migraine+surgery+statement.pdf. Accessed November 18, 2012.
65. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011; 31: 271-285.
66. Lipton RB, et al. PRISM study: Occipital nerve stimulation for treatment-refractory migraine [abstract PO47]. Cephalalgia. 2009; 29 (Suppl.): 30.
67. Serra G, Marchloretta F,. Occipital nerve stimulation for chronic migraine: A randomized trial. Pain Physician. 2012; 15: 245-253.
68. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012; 32: 1165-1179.
69. Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB,. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011; 76: 711-718.
70. Seok JI, Cho HI, Chung CS,. From transformed migraine to episodic migraine: Reversion factors. Headache. 2006; 46: 1186-1190.
71. Irimia P, Palma JA, Fernandez-Torron R, Martinez-Vila E,. Refractory migraine in a headache clinic population. BMC Neurol. 2011; 11: 94.
72. Shapiro R,. Headache disorders. Pain in America: Exploring challenges to relief. Testimony submitted to the United States Senate, Health, Education, Labor, and Pension Committee. Washington, D.C. 2/14/12. 2012. Available at http://www.aan.com/globals/axon/assets/9369.pdf. Accessed November 18, 2012.